Protalix BioTherapeutics (NYSE:PLX) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Protalix BioTherapeutics (NYSE:PLX - Free Report) from a buy rating to a strong-buy rating in a research report report published on Wednesday.

Separately, HC Wainwright upped their price target on Protalix BioTherapeutics from $10.00 to $15.00 and gave the company a "buy" rating in a research report on Monday, February 3rd.

Protalix BioTherapeutics Stock Up 3.2 %

Shares of NYSE PLX traded up $0.07 during mid-day trading on Wednesday, hitting $2.24. 696,153 shares of the company traded hands, compared to its average volume of 420,804. Protalix BioTherapeutics has a 1 year low of $0.82 and a 1 year high of $2.76. The stock has a market capitalization of $164.94 million, a price-to-earnings ratio of -17.23 and a beta of 0.72. The business has a 50 day moving average of $2.38 and a two-hundred day moving average of $1.71.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Y Intercept Hong Kong Ltd acquired a new position in Protalix BioTherapeutics in the 4th quarter worth about $35,000. PFG Investments LLC acquired a new position in Protalix BioTherapeutics in the 4th quarter worth about $39,000. Cubist Systematic Strategies LLC increased its position in Protalix BioTherapeutics by 24.1% in the 4th quarter. Cubist Systematic Strategies LLC now owns 29,307 shares of the company's stock worth $55,000 after purchasing an additional 5,686 shares during the last quarter. XTX Topco Ltd acquired a new position in Protalix BioTherapeutics in the 3rd quarter worth about $36,000. Finally, Prudential Financial Inc. acquired a new position in Protalix BioTherapeutics in the 4th quarter worth about $68,000. 16.53% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.